Aeolus Pharmaceuticals (AOLS) stock price, revenue, and financials

Aeolus Pharmaceuticals annual revenue was $2.08 m in FY 2016

$13 K

Aeolus Pharmaceuticals Revenue Q3, 2017
Aeolus Pharmaceuticals Net income (Q3, 2017)-949 K
Aeolus Pharmaceuticals EBIT (Q3, 2017)-949 K
Aeolus Pharmaceuticals Cash, 30-Jun-2017403 K

Aeolus Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016

Revenue

3.9m3.1m2.1m

Revenue growth, %

(33%)

R&D expense

3.4m3.5m2.9m

General and administrative expense

3.3m2.2m2.5m

Operating expense total

6.6m5.7m5.3m

EBIT

(2.7m)(2.6m)(3.3m)

EBIT margin, %

(69%)(84%)(158%)

Interest expense

2.0k285.0k

Net Income

(3.2m)(2.6m)(3.6m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.4m5.0m925.0k1.2m63.0k305.0k660.0k83.0k129.0k13.0k

R&D expense

1.2m2.8m973.0k1.3m269.0k492.0k904.0k489.0k594.0k425.0k

General and administrative expense

702.0k577.0k650.0k604.0k578.0k561.0k628.0k681.0k570.0k537.0k

Operating expense total

1.9m3.4m1.6m1.9m847.0k1.1m1.5m1.2m1.2m962.0k

EBIT

(437.0k)1.6m(698.0k)(712.0k)(748.0k)(872.0k)(1.1m)(1.0m)(949.0k)

EBIT margin, %

(30%)32%(75%)(60%)(245%)(132%)(1310%)(802%)(7300%)

Interest expense

285.0k

Net Income

(437.0k)1.6m(698.0k)(712.0k)(784.0k)(1.0m)(872.0k)(1.1m)(1.0m)(949.0k)

Aeolus Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016

Cash

869.0k94.0k3.2m

Accounts Receivable

370.0k1.6m750.0k

Current Assets

1.9m1.7m4.1m

Total Assets

2.0m1.8m4.2m

Accounts Payable

579.0k1.6m972.0k

Current Liabilities

1.3m2.6m972.0k

Total Liabilities

1.3m2.6m972.0k

Additional Paid-in Capital

183.3m184.4m191.9m

Retained Earnings

(183.9m)(186.6m)(190.2m)

Total Equity

705.0k(845.0k)3.2m

Financial Leverage

2.8 x-2.1 x1.3 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

520.0k1.3m447.0k248.0k416.0k5.4m3.8m1.9m981.0k403.0k

Accounts Receivable

1.8m2.7m1.8m1.8m656.0k871.0k742.0k544.0k603.0k313.0k

Current Assets

3.9m4.9m2.7m2.2m1.2m6.4m4.8m2.6m1.7m762.0k

Total Assets

3.9m4.9m2.8m2.2m1.2m6.4m4.9m2.6m1.8m794.0k

Accounts Payable

2.4m2.4m1.3m1.8m1.5m796.0k661.0k514.0k638.0k587.0k

Current Liabilities

3.9m3.3m1.7m1.8m1.5m796.0k688.0k514.0k638.0k587.0k

Total Liabilities

3.9m1.5m796.0k514.0k587.0k

Additional Paid-in Capital

183.7m183.8m184.4m184.5m184.5m191.8m191.8m191.9m191.9m191.9m

Retained Earnings

(185.1m)(183.5m)(184.7m)(185.4m)(186.2m)(187.7m)(189.2m)(191.3m)(192.3m)(193.3m)

Total Equity

37.0k1.6m1.1m434.0k5.6m4.2m2.1m1.1m207.0k

Financial Leverage

105.1 x3 x2.6 x5.2 x1.1 x1.2 x1.2 x1.6 x3.8 x

Aeolus Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2015FY, 2016

Net Income

(3.2m)(2.6m)(3.6m)

Depreciation and Amortization

6.0k

Accounts Receivable

411.0k(26.0k)835.0k

Accounts Payable

(1.6m)46.0k(626.0k)

Cash From Operating Activities

(3.0m)(2.4m)(3.1m)

Cash From Financing Activities

3.6m1.0m6.2m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(1.1m)1.6m(698.0k)(712.0k)(2.2m)(1.0m)(872.0k)(1.1m)(1.0m)(3.1m)

Accounts Receivable

(1.5m)2.7m1.8m1.8m903.0k714.0k742.0k206.0k603.0k437.0k

Accounts Payable

1.8m2.4m1.3m1.8m(87.0k)(802.0k)661.0k(458.0k)638.0k(385.0k)

Cash From Operating Activities

(349.0k)(1.1m)(820.0k)(1.3m)(2.8m)

Cash From Financing Activities

20.0k6.2m

Aeolus Pharmaceuticals Ratios

USDY, 2017

Revenue/Employee

3.3k

Financial Leverage

3.8 x